Compare Gilead Sciences, Inc. (GILD) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Micron Technology, Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.11 (market cap $163.51B), while Micron Technology, Inc. trades at $867.05 (market cap $1.02T). The key difference: Micron Technology, Inc. is far larger — about 6.2× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MU | |
|---|---|---|
Market Cap | $163.51B | $1.02T |
Sector | Health | Technology |
52-Week High | $155.80 | $1.21K |
52-Week Low | $108.22 | $104.88 |
Enterprise Value | $178.05B | $1.00T |
Dividend Yield | 2.49% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Micron Technology (MU) trades at $983.12, up 4.92% in the last 24 hours, with a bullish technical signal and strong fundamental momentum. The company has consistently beaten earnings estimates, with Q1 2026 EPS of $25.11 surpassing the $20.98 forecast. Revenue growth is robust, rising to $37.38 billion in 2025, while profitability metrics like a 55.91% net income margin and 32.62% ROE highlight operational efficiency. Recent news reflects mixed sentiment amid AI-driven demand and competitive pressures from Chinese memory makers.
The outlook for MU is positive, driven by AI infrastructure demand and earnings strength, but risks include fierce competition and market volatility. Analysts are overwhelmingly bullish, with an 81.43% buy rating and a consensus price target of $1,550, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
